Significant evidence, based on results of preclinical studies and observations in humans, indicates that energy metabolic derangements contribute to the development of heart failure. A prototypical fuel shift occurs in the hypertrophied and failing heart, in which the capacity for oxidizing fatty acids, the chief substrate for the normal adult heart, becomes reduced along with an increase in reliance on glucose. It is generally believed that reduced capacity for oxidation of fatty acids leads to an energy-starved heart. Therefore, identification of alternate fuel utilization pathways that may compensate for this fuel shift could lead to new therapeutic strategies aimed at heart failure. In this study, using well-defined mouse models of cardiac hypertrophy and heart failure, we demonstrate that the heart begins to utilize ketone bodies en route to the development of heart failure. This shift to reliance on ketone bodies as a fuel is likely driven by multiple mechanisms, including elevation in plasma ketones, a reduction in competition with fatty acids, and gene regulatory reprogramming of the heart. These findings set the stage for future studies aimed at determining whether the shift to oxidizing ketone bodies in the failing heart is adaptive or maladaptive. This fuel utilization pathway could prove to be a new candidate target for metabolic modulatory therapies aimed at early stages of heart failure. See p 698.
Evidence for Intramyocardial Disruption of Lipid Metabolism and Increased Myocardial Ketone Utilization in Advanced Human Heart Failure
Human heart failure is a progressive syndrome that remains associated with significant mortality. Our understanding of disease progression within the hemodynamic and neurohormonal paradigms has been elucidated to a great extent, allowing therapeutic advances that have improved symptoms and survival. However, the metabolic adaptations of the failing human heart remain elusive, precluding the development of therapeutic strategies that can enhance the efficiency and energetics of failing myocardium. Furthermore, our understanding of the transition from hypertrophy to failure is also rudimentary in humans, including the metabolic changes that take place. In this report, we describe the characteristic lipid signature of end-stage failing myocardium in advanced heart failure, marked by: (1) a significant decrease in long-chain acylcarnitines;
(2) a decrease in the myocardial metabolite pool of downstream tricarboxylic acid cycle intermediates, including succinyl-coenzyme A, despite increased myocardial acetyl-coenzyme A; (3) increased myocardial utilization of β-hydroxybutyrate and upregulation of genes implicated in myocardial ketone oxidation including the succinyl-coenzyme A transferase (succinyl-CoA:3-oxoacid CoA transferase). Based on these novel observations, our enhanced understanding of the metabolic signature in nondiabetic heart failure may allow translation into therapeutic strategies that could decelerate disease progression or even reverse the cardiomyopathic burden in our patients with chronic heart failure. See p 706.
SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction
Pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) represents the most frequent cause of pulmonary hypertension worldwide, with no currently approved therapies. A major risk factor for the development of PH-HFpEF is metabolic syndrome. Although, at present, there are more than 10 US Food and Drug Administration-approved drugs to treat pulmonary arterial hypertension available on the market, all clinical trials with pulmonary arterial hypertension drugs have targeted patients with normal left ventricular filling pressures and are contraindicated in patients with PH-HFpEF. In this study, we show that oral treatment with nitrite or metformin targets both metabolic syndrome and the pulmonary vasculature, improving insulin sensitivity and reducing pulmonary pressures and vascular remodeling in a novel rat model of PH-HFpEF. These effects are caused by direct action on skeletal muscle, with activation of SIRT3-AMPK-GLUT4, which enhances skeletal muscle glucose uptake. We also confirm in patients with metabolic syndrome that chronic oral therapy with nitrite and nitrate similarly increases skeletal muscle SIRT3 and AMP-activated protein kinase activation. Thus, our study suggests a potential role for nitrite and metformin as preventative treatments for PH-HFpEF developing in patients with metabolic syndrome and identifies skeletal muscle SIRT3 as a potential therapeutic target in the management of PH-HFpEF. Future trials of chronic oral nitrite and oral metformin, alone or in combination, may be considered for patients with PH-HFpEF. See p 717.
Herpesvirus Infections and Childhood Arterial Ischemic Stroke: Results of the VIPS Study
In this prospective, multicenter study, investigators from the International Pediatric Stroke Study consortium found serological evidence that herpesviruses act as a trigger for childhood arterial ischemic stroke. Varicella zoster virus is an established cause of stroke, known to directly invade the distal internal carotid artery and its major branches, and cause a focal vasculitis. It has also recently been implicated as a cause of giant cell arteritis. This study suggests a role for other herpesvirus, particularly herpes simplex virus type 1. Although cases with stroke were similar to controls in rates of past herpesvirus infection, cases were significantly more likely to have an acute herpesvirus infection, even after controlling for age and socioeconomic status. Among cases with serological analyses of acute and convalescent blood samples, almost half had an acute herpesvirus infection, mostly herpes simplex virus (40% of cases), with fewer cases of varicella zoster virus, cytomegalovirus, and Epstein-Barr virus. Most had serologies consistent with a primary infection, meaning a first-ever infection in a previously seronegative 
